Last updated on February 2018

Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC)

Brief description of study

Purpose The TARGET All comers trial is a prospective, multicenter, randomized, two-arm, non-inferiority, open-label study with 1656 patients at 20 centers in Europe. The study is a "real world, all comers" study.

Detailed Study Description

Primary objective: to compare the MicroPort Medical (Group) Co., Ltd Firehawkcobalt chromium coronary stent ( rapamycin target eluting ) system with abluminal grooves containing a biodegradable polymer with the Abbott XIENCE family EES (Everolimus-Eluting stent) system with respect to cardiac death, myocardial infarction (not clearly attributable to a non-target vessel), Target Lesion Revascularization at 1 year in a "real world" patient population.

Clinical Study Identifier: NCT02520180

Contact Investigators or Research Sites near you

Start Over

Lene Holmvang, MD

Copenhagen, Denmark
  Connect »